More from Novartis (NVS): 2011 will be challenging, with the patent loss of heart drug Diovan...

|About: Novartis AG (NVS)|By:, SA News Editor
More from Novartis (NVS): 2011 will be challenging, with the patent loss of heart drug Diovan (annual sales of $6B+), and cancer drug Femara ($1B+). U.S. healthcare reform will also reduce drug prices. Expects 'accelerating growth' in 2013 and 2014 once the patent loss effect eases. (also)